Blundell Tom L, Patel S
Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1QW, UK.
Curr Opin Pharmacol. 2004 Oct;4(5):490-6. doi: 10.1016/j.coph.2004.04.007.
Knowledge of the three-dimensional structures of protein targets has the potential to greatly accelerate drug discovery, but technical challenges and time constraints have traditionally limited its use to lead optimization. Its application is now being extended beyond structure determination into new approaches for lead discovery. Structure-activity relationships by nuclear magnetic resonance have been widely used to detect ligand binding and to give some indication of the location of the binding site. X-ray crystallography has the advantage of defining ligand-binding sites with greater certainty. High-throughput approaches make this method applicable to screening to identify molecular fragments that bind protein targets, and to defining precisely their binding sites. X-ray crystallography can then be used as a rapid technique to guide the elaboration of the fragments into larger molecular weight compounds that might be useful leads for drug discovery.
了解蛋白质靶点的三维结构有潜力极大地加速药物研发,但传统上技术挑战和时间限制使其应用仅限于先导化合物优化。如今,其应用正从结构测定扩展到先导化合物发现的新方法。通过核磁共振确定的构效关系已被广泛用于检测配体结合,并对结合位点的位置提供一些指示。X射线晶体学的优势在于能更确切地定义配体结合位点。高通量方法使该方法适用于筛选,以识别与蛋白质靶点结合的分子片段,并精确确定其结合位点。然后,X射线晶体学可作为一种快速技术,指导将这些片段构建成分子量更大的化合物,这些化合物可能是药物研发中有用的先导化合物。